Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

被引：0
|
作者：
Lori J. Goldstein
Raymond P. Perez
Denise Yardley
Linda K. Han
James M. Reuben
Hui Gao
Susan McCanna
Beth Butler
Pier Adelchi Ruffini
Yi Liu
Roberto R. Rosato
Jenny C. Chang
机构：
[1] The Hospital of Fox Chase Cancer Center,Department of Medical Oncology
[2] University of Kansas Medical Research Center,Department of Hematopathology–Research
[3] Current address: Early Oncology Development,undefined
[4] Bristol-Myers Squibb,undefined
[5] Tennessee Oncology,undefined
[6] Indiana University Simon Cancer Center,undefined
[7] Current address: Parkview Cancer Institute,undefined
[8] MD Anderson Cancer Center,undefined
[9] Research and Development,undefined
[10] Dompé farmaceutici S.p.A.,undefined
[11] The Methodist Hospital Research Institute,undefined
[12] Sarah Cannon Research Institute,undefined
来源：
Breast Cancer Research | / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
An amendment to this paper has been published and can be accessed via the original article.
引用
收藏
相关论文
共 50 条
  • [31] Capecitabine Monotherapy: Review of Studies in First-Line HER-2-Negative Metastatic Breast Cancer
    O'Shaughnessy, Joyce A.
    Kaufmann, Manfred
    Siedentopf, Friederike
    Dalivoust, Philippe
    Debled, Marc
    Robert, Nicholas J.
    Harbeck, Nadia
    ONCOLOGIST, 2012, 17 (04): : 476 - 484
  • [32] CXCR1/2 signalling regulates human breast cancer stem cell activity
    Singh, J. K.
    Farnie, G.
    Clarke, R. B.
    Bundred, N. J.
    BRITISH JOURNAL OF SURGERY, 2012, 99 : 8 - 9
  • [33] SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naive, early breast cancer
    Oliveira, M.
    Cejalvo Andujar, J. M.
    Margeli Vila, M.
    Tolosa Ortega, P.
    Martinez Saez, O.
    Salvador Bofill, F. J.
    Cruz Jurado, J.
    Barrera, A. M. Luna
    Arumi De Dios, M. A.
    Vidal Losada, M. J.
    Guerra, J. A.
    Pernas Simon, S.
    Villacampa Javierre, G.
    Gonzalez-Farre, B.
    Sanfeliu Torres, E.
    Santhanagopal, A.
    Falato, C.
    Ferrero Cafiero, J. M.
    Pascual, T.
    Prat, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S628 - S628
  • [34] Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations
    Shunchao Yan
    Murshid Imam
    Discover Oncology, 14
  • [35] Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer
    Park, Changhee
    Suh, Koung Jin
    Kim, Se Hyun
    Lee, Kyung-Hun
    Im, Seock-Ah
    Kim, Min Hwan
    Sohn, Joohyuk
    Jeong, Jae Ho
    Jung, Kyung Hae
    Lee, Kyoung Eun
    Park, Yeon Hee
    Kim, Hee-Jun
    Cho, Eun Kyung
    Choi, In Sil
    Noh, Seung-Jae
    Shin, Inkyung
    Cho, Dae-Yeon
    Kim, Jee Hyun
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (10)
  • [36] CXCR1/2 Regulates Human Breast Cancer Stem Cell Activity Via EGFR/HER2-Dependent and -Independent Pathway.
    Singh, J. K.
    Farnie, G.
    Clarke, R. B.
    Bundred, N. J.
    CANCER RESEARCH, 2011, 71
  • [37] Efficacy of everolimus combined with endocrine therapy in HR-positive/HER-2-negative advanced breast cancer
    Song, Xifu
    Lu, Jingjing
    Wang, Liyan
    Kong, Feifei
    Yuan, Hangyu
    Chen, Cheng
    Shan, Haixia
    JOURNAL OF BUON, 2020, 25 (05): : 2228 - 2236
  • [38] Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
    Singh, Jagdeep K.
    Farnie, Gillian
    Bundred, Nigel J.
    Simoes, Bruno M.
    Shergill, Amrita
    Landberg, Goeran
    Howell, Sacha J.
    Clarke, Robert B.
    CLINICAL CANCER RESEARCH, 2013, 19 (03) : 643 - 656
  • [39] Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations
    Yan, Shunchao
    Imam, Murshid
    DISCOVER ONCOLOGY, 2023, 14 (01)
  • [40] VENTANA (SOLTI-1501): Oral metronomic vinorelbine combined with endocrine therapy in Eluminal/HER2-negative early breast cancer: A window of opportunity trial
    Adamo, B.
    Vidal, M.
    Gomez Pardo, P.
    Zaragoza, K.
    Ciruelos, E.
    Virizuela, J. A.
    Blanch Tormo, S.
    Perez-Fidalgo, J. A.
    Murillo, L.
    Lopez-Gonzalez, A.
    Amillano Parraga, K.
    Martinez Janez, N.
    Gonzalez Farre, X.
    Prat, A.
    CANCER RESEARCH, 2017, 77
12345